MOESM4 of Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Additional file 4. Available patient numbers (N) for analysis of distribution profiles of CD8+ and CD4+ T cells and subsets in Fig. 4.